| Revenue growth | ₹904cr in Q4 (-5% YoY); ₹2,461cr India revenue in FY26 (+9%). |
|---|---|
| Margins | Gross margin improved to 70%; adjusted EBITDA margin expanded 200bps to 27%. |
| Demand visibility | Branded business remains a double-digit growth driver; chronic growing at 19%. |
| Management confidence | High confidence in India branded business acceleration post-integration. |
Growth
Revenue ₹904cr (-5% YoY); adjusted EBITDA ₹241cr; adjusted PAT ₹150cr. Branded India business grew 11% in FY26.
Outlook
Merger with Torrent Pharma effective in 1-2 months. Guidance for gradual recovery to double-digit growth in India business.
Risks
Trade generics discontinuation impacting top-line; container constraints in West Asia and Asia; integration-led operational resets.
Earnings Call filed with BSE, NSE: JBCHEPHARM. Summary written with AI assistance from the document.
More from J B Chemicals & Pharmaceuticals Ltd
All →Jb Chemicals & Pharmaceuticals Merger & Restructuring
JB Chemicals & Pharmaceuticals' amalgamation with Torrent Pharmaceuticals received NCLT sanction. The scheme will become effective upon filing with the Registrar of Companies.
Jb Chemicals & Pharmaceuticals Management Change
Pradeep Kumar Singh and Suresh Bhise retired from the company. These changes in senior management are effective from June 30, 2026.
Jb Chemicals & Pharmaceuticals Price Movement Clarification
JB Chemicals clarified its audited financial results to the exchange. The board-approved results were signed by a director as authorized.
Jb Chemicals & Pharmaceuticals Management Change
Mr. Bhushan Sachdev resigned as Executive Vice President – Supply Chain Management effective June 12, 2026. Investors should note the departure of a key supply chain executive.
Jb Chemicals & Pharmaceuticals Annual Report
JB Chemicals & Pharmaceuticals Limited filed its Business Responsibility and Sustainability Report for FY 2025-26. The report details company ESG performance, sustainability targets, and governance frameworks.
Jb Chemicals & Pharmaceuticals Annual Report
JB Chemicals & Pharmaceuticals filed its FY26 Business Responsibility and Sustainability Report. The filing highlights its ₹3889.89 Crore turnover and ESG progress for investor review.
- Value
- ₹3,890 Cr